AURKA and MAP2K1

Data Source:
BioGRID (two hybrid)

		AURKA	MAP2K1
Description		aurora kinase A	mitogen-activated protein kinase kinase 1
Image
GO Annotations	Cellular Component	Nucleus Nucleoplasm Centrosome Centriole Spindle Cytosol Spindle Microtubule Cilium Microtubule Cytoskeleton Midbody Spindle Pole Centrosome Chromosome Passenger Complex Germinal Vesicle Axon Hillock Pronucleus Perinuclear Region Of Cytoplasm Spindle Midzone Meiotic Spindle Mitotic Spindle Pole	Nucleus Mitochondrion Early Endosome Late Endosome Endoplasmic Reticulum Golgi Apparatus Microtubule Organizing Center Cytosol Plasma Membrane Focal Adhesion
	Molecular Function	Protein Kinase Activity Protein Serine/threonine Kinase Activity Protein Serine/threonine/tyrosine Kinase Activity Protein Binding ATP Binding Protein Kinase Binding Ubiquitin Protein Ligase Binding Histone Serine Kinase Activity Protein Heterodimerization Activity Protein Serine Kinase Activity Protein Threonine Kinase Activity	Protein Kinase Activity Protein Serine/threonine Kinase Activity MAP Kinase Kinase Activity Protein Serine/threonine/tyrosine Kinase Activity Protein Tyrosine Kinase Activity MAP-kinase Scaffold Activity Protein Binding ATP Binding Protein C-terminus Binding Protein Serine/threonine Kinase Activator Activity Protein N-terminus Binding Scaffold Protein Binding
	Biological Process	G2/M Transition Of Mitotic Cell Cycle Mitotic Cell Cycle Protein Phosphorylation Ubiquitin-dependent Protein Catabolic Process DNA Damage Response, Signal Transduction By P53 Class Mediator Resulting In Cell Cycle Arrest Spindle Organization Mitotic Spindle Organization Spindle Assembly Involved In Female Meiosis I Mitotic Centrosome Separation Response To Wounding Anterior/posterior Axis Specification Regulation Of G2/M Transition Of Mitotic Cell Cycle Negative Regulation Of Gene Expression Negative Regulation Of G2/M Transition Of Mitotic Cell Cycle Peptidyl-serine Phosphorylation Anaphase-promoting Complex-dependent Catabolic Process Regulation Of Protein Stability Negative Regulation Of Protein Binding Positive Regulation Of Proteasomal Ubiquitin-dependent Protein Catabolic Process Regulation Of Cytokinesis Histone-serine Phosphorylation Negative Regulation Of Apoptotic Process Positive Regulation Of Mitotic Nuclear Division Regulation Of Centrosome Cycle Protein Autophosphorylation Cell Division Centrosome Localization Protein Localization To Centrosome Liver Regeneration Positive Regulation Of Oocyte Maturation Regulation Of Signal Transduction By P53 Class Mediator Neuron Projection Extension	MAPK Cascade Activation Of MAPK Activity Protein Phosphorylation Chemotaxis Cell Cycle Arrest Signal Transduction Heart Development Negative Regulation Of Cell Population Proliferation Positive Regulation Of Gene Expression Negative Regulation Of Gene Expression Peptidyl-threonine Phosphorylation Peptidyl-tyrosine Phosphorylation Cerebellar Cortex Formation Neuron Differentiation Keratinocyte Differentiation Thyroid Gland Development Regulation Of Stress-activated MAPK Cascade Positive Regulation Of Transcription, DNA-templated Thymus Development Regulation Of Axon Regeneration Cell Motility Positive Regulation Of Axonogenesis Bergmann Glial Cell Differentiation Face Development Trachea Formation Epithelial Cell Proliferation Involved In Lung Morphogenesis Placenta Blood Vessel Development Labyrinthine Layer Development ERK1 And ERK2 Cascade Positive Regulation Of ERK1 And ERK2 Cascade Positive Regulation Of Protein Serine/threonine Kinase Activity Regulation Of Golgi Inheritance Cellular Senescence Positive Regulation Of Production Of MiRNAs Involved In Gene Silencing By MiRNA Regulation Of Early Endosome To Late Endosome Transport
Pathways		APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 Regulation of PLK1 Activity at G2/M Transition SUMOylation of DNA replication proteins TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest Regulation of TP53 Activity through Phosphorylation FBXL7 down-regulates AURKA during mitotic entry and in early mitosis AURKA Activation by TPX2 Interaction between PHLDA1 and AURKA	MAPK3 (ERK1) activation Frs2-mediated activation Signal transduction by L1 Uptake and function of anthrax toxins RAF activation MAP2K and MAPK activation Negative feedback regulation of MAPK pathway MAP3K8 (TPL2)-dependent MAPK1/3 activation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by MAP2K mutants Signaling by RAF1 mutants
Drugs		Phosphonothreonine AT9283 CYC116 Alisertib SNS-314 Cenisertib Enzastaurin 4-(4-METHYLPIPERAZIN-1-YL)-N-[5-(2-THIENYLACETYL)-1,5-DIHYDROPYRROLO[3,4-C]PYRAZOL-3-YL]BENZAMIDE AKI-001 1-{5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-1,3-thiazol-2-yl}-3-[3-(trifluoromethyl)phenyl]urea 1-(5-{2-[(1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino]ethyl}-1,3-thiazol-2-yl)-3-[3-(trifluoromethyl)phenyl]urea N-{3-[(4-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-2-YL)AMINO]PHENYL}CYCLOPROPANECARBOXAMIDE N-butyl-3-{[6-(9H-purin-6-ylamino)hexanoyl]amino}benzamide 2-(1H-pyrazol-3-yl)-1H-benzimidazole N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDE Fostamatinib MLN8054	K-252a 5-Bromo-N-[(2S)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide Cobimetinib Bosutinib (5S)-4,5-difluoro-6-[(2-fluoro-4-iodophenyl)imino]-N-(2-hydroxyethoxy)cyclohexa-1,3-diene-1-carboxamide 2-[(2-chloro-4-iodophenyl)amino]-N-{[(2R)-2,3-dihydroxypropyl]oxy}-3,4-difluorobenzamide PD-0325901 N-(5-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-1,3,4-oxadiazol-2-yl)ethane-1,2-diamine 2-[(4-ETHYNYL-2-FLUOROPHENYL)AMINO]-3,4-DIFLUORO-N-(2-HYDROXYETHOXY)BENZAMIDE Trametinib Selumetinib
Diseases			Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
GWAS		Mean corpuscular hemoglobin ( 32888494) Mean corpuscular volume ( 32888494) Mean spheric corpuscular volume ( 32888494) Metabolite levels ( 23823483)	Prostate cancer ( 29892016) Testicular germ cell tumor ( 28604728 28604732)
Interacting Genes		170 interacting genes: AATF AKT1 ANGPTL4 ANP32B APP ARPC1B ARPC2 ATRX AUNIP AURKAIP1 BAAT BCL2L1 BEX2 BIRC5 BLID BORA BRAF BRCA1 BTK CBX3 CCND2 CCNE1 CDC20 CDC25B CDH13 CDK8 CHFR CKAP5 CORO2A CSN2 CTCFL CYLC2 DACH1 DKK3 EHMT2 EPHA2 EPSTI1 ERBB2 ERRFI1 FANCA FBP2 FOXF1 FOXP1 FZR1 GADD45A GMNN GSK3B GTF3C4 H3-4 H3C1 HDAC2 HDAC6 HEMGN HIF1A HNRNPF HNRNPK IFI16 IGFBP3 IKBKB INCENP KIF11 KIF2C KLHL18 KLK5 LATS2 LEF1 LYPD3 MAP2K1 MAP2K3 MAP3K5 MAPK3 MAPRE2 MAPRE3 MBD3 MBP MDM2 MED26 MTA3 MYC MYT1 MYT1L NANS NAT2 NDC80 NEDD9 NF2 NFKBIA NFXL1 NIN NKX1-1 NME1 NSD2 NUF2 OTUB1 OTUD7B PARP10 PAX4 PAX8 PDGFRA PDLIM2 PLK3 PML POU4F3 PPP1CA PPP1CB PPP1CC PPP2CB PPP3R2 PRKACA PSEN2 PSMC3IP PTPRD PTTG1 PUM2 RASA1 RASSF1 RELA REST S100A14 SCGB3A1 SEC61B SFRP4 SIN3B SOX18 SOX3 SOX30 SOX4 SREBF2 SRPK1 SRPK2 SSRP1 STAT2 STK11 STX17 SUPT20H SWT1 TACC1 TACC3 TBC1D2 TBX10 TCEAL2 TCERG1 TCF3 TEAD2 TFAP2B TGFB1 THRSP TLK1 TLK2 TP53 TP73 TPX2 TRMO TRRAP TSC1 TSTD2 UBE2C UBE2I UBE2N UBTF USP2 USP21 VHL WIF1 XPA YY1 ZFHX3 ZKSCAN2 ZNF189 ZNF510	67 interacting genes: APC ARAF AURKA BANP BAX BIRC6 BMPR1A BRAF BUB1 CASP9 CDH1 CDK5 CDKN2A CPNE1 CPNE4 CTNNA1 EGFR ELK1 EP300 ERBB2 FBXW7 GRB10 HNRNPD HRAS KAT7 KSR1 KSR2 LAMTOR3 MAP3K4 MAP3K8 MAPK1 MAPK14 MAPK3 MAPK8 MAPK8IP3 MBP MLH3 MSH6 MYC ODC1 PAK1 PARVA PDGFRL PEBP1 PEBP4 PIK3CA PLEKHF2 PLK3 PPARG PRKCI PRKCZ PTPRJ RAF1 RPS6KA2 RPS6KA4 SMAD2 SRC STK11 TCP11 TGFBR2 TLR2 TRAF3 TRAF6 TRIB1 UBE2I UBE2L3 WNK1
Entrez ID		6790	5604
HPRD ID		04066	01469
Ensembl ID		ENSG00000087586	ENSG00000169032
Uniprot IDs		O14965	A4QPA9 B4DFY5 H3BRW9 Q02750
PDB IDs		1MQ4 1MUO 1OL5 1OL6 1OL7 2BMC 2C6D 2C6E 2DWB 2J4Z 2J50 2NP8 2W1C 2W1D 2W1E 2W1F 2W1G 2WQE 2WTV 2WTW 2X6D 2X6E 2X81 2XNE 2XNG 2XRU 3COH 3E5A 3EFW 3FDN 3H0Y 3H0Z 3H10 3HA6 3K5U 3LAU 3M11 3MYG 3NRM 3O50 3O51 3P9J 3QBN 3R21 3R22 3UNZ 3UO4 3UO5 3UO6 3UOD 3UOH 3UOJ 3UOK 3UOL 3UP2 3UP7 3VAP 3W10 3W16 3W18 3W2C 4B0G 4BN1 4BYI 4BYJ 4C3P 4C3R 4CEG 4DEA 4DEB 4DED 4DEE 4DHF 4J8M 4J8N 4JAI 4JAJ 4JBO 4JBP 4JBQ 4O0S 4O0U 4O0W 4PRJ 4UYN 4UZD 4UZH 4ZS0 4ZTQ 4ZTR 4ZTS 5AAD 5AAE 5AAF 5AAG 5DN3 5DNR 5DOS 5DPV 5DR2 5DR6 5DR9 5DRD 5DT0 5DT3 5DT4 5EW9 5G15 5G1X 5L8J 5L8K 5L8L 5LXM 5OBJ 5OBR 5ODT 5ONE 5ORL 5ORN 5ORO 5ORP 5ORR 5ORS 5ORT 5ORV 5ORW 5ORX 5ORY 5ORZ 5OS0 5OS1 5OS2 5OS3 5OS4 5OS5 5OS6 5OSD 5OSE 5OSF 5ZAN 6C2R 6C2T 6C83 6CPE 6CPF 6CPG 6GRA 6HJJ 6HJK 6I2U 6R49 6R4A 6R4B 6R4C 6R4D 6VPG 6VPH 6VPI 6VPJ 6VPL 6VPM 6XKA 6Z4Y	1S9J 2P55 3DV3 3DY7 3E8N 3EQB 3EQC 3EQD 3EQF 3EQG 3EQH 3EQI 3MBL 3ORN 3OS3 3PP1 3SLS 3V01 3V04 3VVH 3W8Q 3WIG 3ZLS 3ZLW 3ZLX 3ZLY 3ZM4 4AN2 4AN3 4AN9 4ANB 4ARK 4LMN 4MNE 4U7Z 4U80 4U81 5BX0 5EYM 5HZE 5YT3 6NYB 6PP9 6Q0J 6Q0T 6U2G 6X2P 6X2S 6X2X
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?